Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin’s Lymphoma (NCT00867087)
The purpose of this study is to evaluate inotuzumab ozogamicin (also known as CMC-544) in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin’s lymphoma.
- Condition: B-Cell Lymphoma
- Phase: II
- Enrollment: 65
- Start: June 2009
- Completion: October 2012
- Last verified: December 2013
Last Editorial review: July 30, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.